18F-PSMA-1007 multiparametric, dynamic PET/CT in biochemical relapse and progression of prostate cancer (original) (raw)
68Ga-PSMA-11 Dynamic PET/CT Imaging in Primary Prostate Cancer
Antonia Dimitrakopoulou-Strauss
Clinical Nuclear Medicine, 2016
View PDFchevron_right
Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer
Nasia Papachristodoulou
European Journal of Nuclear Medicine and Molecular Imaging, 2018
View PDFchevron_right
A Prospective Study on 18F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer
Kim Chi
Journal of Nuclear Medicine
View PDFchevron_right
The Impact of 18F-DCFPyL PSMA PET-CT in the Management of Prostate Cancer Biochemical Recurrence
Pablo Sopena
Open Journal of Urology, 2021
View PDFchevron_right
Non-prostate cancer tumours: incidence on 18F-DCFPyL PSMA PET/CT and uptake characteristics in 1445 patients
Kim Taubman
European Journal of Nuclear Medicine and Molecular Imaging, 2022
View PDFchevron_right
Radiation dosimetry and biodistribution of 18F-PSMA-11 for PET imaging of prostate cancer
Sarah Piron
Journal of Nuclear Medicine
View PDFchevron_right
Detection efficacy of [18F]PSMA-1007 PET/CT in 251 Patients with biochemical recurrence after radical prostatectomy
Fabian Spohn
Journal of Nuclear Medicine
View PDFchevron_right
Clinical impact of PSMA-based 18F–DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy
Ronnie Mease
European Journal of Nuclear Medicine and Molecular Imaging, 2017
View PDFchevron_right
Incremental Value of Post Diuretic 68Ga-PSMA-11 PET-CT in Characterization of Indeterminate lLesions in Prostate Cancer
Fahad Marafi
Asian Pacific Journal of Cancer Prevention
View PDFchevron_right
Evaluation of hybrid PET/CT imaging with the 68Ga-labelled PSMA ligand in patients with prostate cancer and biochemical progression in the low-range values of PSA after radical prostatectomy
Klara Dokova
Scripta Scientifica Medica, 2022
View PDFchevron_right
Analysis of Pros and Cons in Using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007: Production, Costs, and PET/CT Applications in Patients with Prostate Cancer
Michela Aurilio
Molecules
View PDFchevron_right
{"__content__"=>"Detection efficacy of [F]PSMA-1007 PET/CT in 251 Patients with biochemical recurrence after radical prostatectomy.", "sup"=>{"__content__"=>"18"}}
Horacio Amaral
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018
View PDFchevron_right
{"__content__"=>"Intra-individual comparison ofF-PSMA-1007 andF-DCFPyL PET/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: A pilot study.", "sup"=>[{"__content__"=>"18"}, {"__content__"=>"18"}]}
Mariza Vorster
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017
View PDFchevron_right
Pilot Comparison of 68Ga-RM2 PET and 68Ga-PSMA PET in Patients with Biochemically Recurrent Prostate Cancer
Steven Hancock
Journal of Nuclear Medicine, 2015
View PDFchevron_right
Clinical Impact of 68Ga-PSMA PET/CT in a Patient With Biochemical Recurrence of Prostate Cancer
Publio Viana
Clinical nuclear medicine, 2016
View PDFchevron_right
Psma for Pet Imaging of Prostate Cancer
Suphansa Kijprayoon
The Bangkok Medical Journal
View PDFchevron_right
68Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer
Rodney Hicks
Cancer imaging : the official publication of the International Cancer Imaging Society, 2017
View PDFchevron_right
Detection Efficacy of Hybrid 68Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria
Armin Ott
Journal of Nuclear Medicine, 2017
View PDFchevron_right
Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology
Fred Verzijlbergen
Prostate Cancer and Prostatic Diseases, 2020
View PDFchevron_right
Pharmacokinetic studies of [68 Ga]Ga-PSMA-11 in patients with biochemical recurrence of prostate cancer: detection, differences in temporal distribution and kinetic modelling by tissue type
Antonia Dimitrakopoulou-Strauss
European Journal of Nuclear Medicine and Molecular Imaging, 2021
View PDFchevron_right
MP77-10 68GALLIUM-PROSTATE-SPECIFIC Membrane Antigen Positron Emission Tomography/Computer Tomography (68GA Psma Pet) Has the Potential to Replace Biopsy in Metastatic Prostate Cancer
Gagan Prakash
The Journal of Urology, 2018
View PDFchevron_right
PET/CT with 11C-choline and 18F-FDG in patients with elevated PSA after radical treatment of a prostate cancer
Paula A. Ramírez Lozano
2009
View PDFchevron_right
Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence
Josef Fritz
European Journal of Nuclear Medicine and Molecular Imaging, 2017
View PDFchevron_right
68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients
Monica Celli
European Journal of Nuclear Medicine and Molecular Imaging, 2018
View PDFchevron_right
68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT
Samuel Samnick
Clinical Nuclear Medicine, 2016
View PDFchevron_right
Detection Rate of 18F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis
Daniele Antonio Pizzuto
Cancers, 2019
View PDFchevron_right
PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer
Ronnie Mease
Molecular Imaging and Biology, 2016
View PDFchevron_right
Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging
Levent Kabasakal
Nuclear Medicine Communications, 2016
View PDFchevron_right
Head to head comparison performance of 99mTc-EDDA/HYNIC-iPSMA SPECT/CT and 68Ga-PSMA-11 PET/CT a prospective study in biochemical recurrence prostate cancer patients
Jenny Davanzo
2018
View PDFchevron_right
Molecular imaging using PSMA PET/CT versus multiparametric MRI for initial staging of prostate cancer: comparing apples with oranges?
Felix Mottaghy
European journal of nuclear medicine and molecular imaging, 2016
View PDFchevron_right
Head- to head Comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as Reference-Standard
Einat Even-sapir
Journal of Nuclear Medicine, 2019
View PDFchevron_right
Restaging the Biochemical Recurrence of Prostate Cancer with [68Ga]Ga-PSMA-11 PET/CT: Diagnostic Performance and Impact on Patient Disease Management
olivier cussenot
Cancers, 2021
View PDFchevron_right
Systemic therapy response evaluation in prostate carcinoma with [68Ga]Ga-PSMA-11 PET/CT
isa guney
Egyptian Journal of Radiology and Nuclear Medicine
View PDFchevron_right
Clinical perspectives of PSMA PET/MRI for prostate cancer
Giovanni Cerri
Clinics (Sao Paulo, Brazil), 2018
View PDFchevron_right
[89Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates
Stephan Maus
European Journal of Nuclear Medicine and Molecular Imaging
View PDFchevron_right